Skip to content
Screener

Sana Biotechnology SANA Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Allogene Therapeutics logo
Allogene TherapeuticsALLO
$81.05M-8.9%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$439.87M-5.9%
Prime Medicine logo
Prime MedicinePRME
$112.48M-6.1%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$73.41M-28.4%
LeMaitre Vascular logo
LeMaitre VascularLMAT
$21.16M+19.7%
Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$1.8M+115%

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$979.59M+32.1%
Enterprise value$971.11M+28.5%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Reported directly by Sana Biotechnology in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:10 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216769
202914,071
20307,758
2031 and thereafter40,943
Total undiscounted lease payments113,772
Less: imputed interest(38,444)
Present value of operating lease liabilities75,328
Less: current portion of operating lease liabilities$(14,878)
Operating lease liabilities, net of current portion$60,450

Item 1. Financial Statements

FAQ

What is Sana Biotechnology's operating lease liabilities (total)?
Sana Biotechnology (SANA) reported operating lease liabilities (total) of $75.33M in Q1 2026.
How has Sana Biotechnology's operating lease liabilities (total) changed year-over-year?
Sana Biotechnology's operating lease liabilities (total) decreased by 17.5% year-over-year, from $91.31M to $75.33M.
What is the long-term trend for Sana Biotechnology's operating lease liabilities (total)?
Over 4 years (2021 to 2025), Sana Biotechnology's operating lease liabilities (total) has grown at a -8.2% compound annual growth rate (CAGR), from $110.94M to $78.86M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Sana Biotechnology's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude